BYM338 vs Darbepoetin Alfa
Head-to-head comparison of BYM338 (Bimagrumab (BYM338)) and Darbepoetin Alfa (Darbepoetin alfa, recombinant human erythropoiesis-stimulating protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | BYM338 | Darbepoetin Alfa |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Bimagrumab (BYM338) | Darbepoetin alfa, recombinant human erythropoiesis-stimulating protein |
| Molecular Weight | ~148 kDa | ≈37,000 Da |
| Half-Life | ~2-3 weeks | ~21 h IV; ~49 h SC |
| Amino Acids | N/A | 165 |
| Typical Dose | 10-30 mg/kg IV in trials | 0.45 mcg/kg weekly SC or 0.75 mcg/kg every 2 weeks |
| Route | Intravenous | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 210 |
| Research Status | Clinical | Clinical |
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Darbepoetin Alfa Benefits
- ✓longer-acting erythropoiesis
- ✓stable hemoglobin
- ✓increased oxygen delivery
- ✓may improve aerobic capacity
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Darbepoetin Alfa Dosing
0.45 mcg/kg weekly SC|0.75 mcg/kg every 2 weeks SC|Dose-adjust to hemoglobin response
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Darbepoetin Alfa Side Effects
- ⚠hypertension
- ⚠thromboembolism
- ⚠headache
Research Overview
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Darbepoetin Alfa
Clinical studies show durable hemoglobin correction with less frequent dosing than epoetin alfa. The endurance benefit, where present, would come from improved oxygen-carrying capacity rather than a direct ergogenic pathway.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.